publication date: Feb. 3, 2017

Drugs & Targets MD Anderson, Guardant form partnership to make liquid biopsy standard of care

MD Anderson Cancer Center and Guardant Health announced a multi-year partnership designed to accelerate comprehensive liquid biopsy technology into the standard of care in cancer treatment.

The commercial, research and development agreement will make MD Anderson among the few hospitals in the world with integrated comprehensive liquid biopsy capabilities.

Under the partnership, Guardant Health will help MD Anderson build multiple on-site liquid biopsy centers enabling development of novel non-invasive assays using Guardant Health’s Digital Sequencing technology. First-of-their-kind interventional clinical utility studies, designed to demonstrate how CLB can improve patient outcomes across multiple types and stages of cancer, will be jointly funded.

The two institutions also will work together on CLB clinical utility studies designed to support incorporation of CLB testing into national guidelines and adoption as a national standard of care.

As an initial step in this partnership, the company’s product will become the preferred liquid biopsy on campus and any MD Anderson physician will be able to order it directly from the electronic medical record system. Since 2014, the test has been used by more than 3,000 oncologists to assess the somatic genomic alterations in more than 30,000 advanced cancer patients.


Indivumed to provide tissue … Continue reading MD Anderson, Guardant form partnership to make liquid biopsy standard of care

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2017 The Cancer Letter Inc.